Items Tagged ‘iNHL’

June 8, 2016

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma


Genentech, announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL). The study compared Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone, head-to-head with Rituxan® (rituximab) plus chemotherapy followed by Rituxan alone. Results from […]

View full entry

Tags: Follicular Lymphoma, GALLIUM study, Gazyva, iNHL, News, nhl, Non-Hodgkin's Lymphoma, non-Hodgkin’s, rituxan, rituximab